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Abstract. Multiple myeloma (MM) is an incurable B lymphocyte cancer. To date, a comparative analysis of global protein
metabolism for the MM cell line CCL-155 (RPMI-8226)
and the non-cancerous B lymphocyte cell line CCL-156
(RPMI‑1788) has not been published. Here, we report that
both global protein synthesis and degradation occur at a higher
rate in MM cells and demonstrate that alkylating agents can
reduce global protein degradation in both cell lines, but the
effect is greater in CCL-156 cells. Treatment with melphalan
plus the proteasome inhibitor MG132 reduced global protein
degradation for MM cells to roughly 60% of that seen without
drugs, but the reduction was approximately three times greater
for CCL-156 cells. This drug combination was growth inhibitory for both cell lines, but CCL-156 inhibition was 2-fold
greater than that of the MM cell line. Additionally, treatment
with melphalan plus the lysosomal inhibitor chloroquine did
not affect growth of MM cells more than melphalan alone,
whereas this combination drastically inhibited growth of
CCL-156 cells despite protein degradation being maintained
at 60% level for both cell lines. This suggests that a lysosomal function other than protein degradation is required
for recovery from alkylation damage in CCL-156 cells. In
general, CCL-156 cells were affected to a greater extent for
both protein degradation and growth inhibition with most drug
combinations tested. Statistical analysis of our data (P=0.066)
provides evidence that aberrant proteasome-mediated protein
degradation correlates with chemoresistance in MM cells, but
that lysosome-mediated protein degradation does not.
Introduction
In the last few years proteasome inhibitors such as bortezomib
(PS-341 or Velcade) have emerged as important chemothera-
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peutic tools to treat multiple myeloma (MM) due to their ability
to modulate the ubiquitin-proteasome system (1-5). Recent,
clinical trials have resulted in very high complete recovery
rates and increased rates of remission and longevity for a
cohort of elderly MM patients when the proteasome inhibitor
bortezomib was added to the classical regimen of melphalan
(Alkeran) plus prednisone (6). The FDA approved the use of
Velcade in the treatment of MM in 2003 (7), although the
molecular mechanism for the enhanced anticancer activity has
not been defined (2,3,8).
Bortezomib is a potent and selective inhibitor of the proteasome, the major site of protein degradation in human cells (9).
The proteasome is a large multi-subunit protein complex that
is localized in the cytoplasm and nucleus and has multiple
sites to rapidly degrade ubiquitinated proteins in a highly
regulated and selective manner. The proteasome has many
disparate roles in cell metabolism including cell signaling,
DNA repair, transcription, cell adhesion and angiogenesis
(1,3,10,11). Bortezomib has been shown to induce apoptosis
by inhibiting transcription factor NF-κ B activation. However,
this activity alone cannot fully explain the anticancer activity
of bortezomib (2,12).
Alkylation damage to DNA by melphalan can block DNA
replication (13). Numerous studies have established a strong
link between DNA repair and the proteasome and it can be
surmised that a fully functional proteasome is essential for
recovery after exposure to DNA damaging agents (14-19). In
fact, proteome protection has been shown to be crucial for cell
survival after exposure to radiation (20). Additionally, protein
adduct formation after melphalan exposure has been observed
and quantification of protein adducts has been proposed as a
method to monitor chemotherapeutic toxicity and mutagenicity in patients (21,22).
The proteasome and the vacuole (an organelle analogous to
the lysosome in mammals) are the two major sites of protein
degradation in yeast (23). We have recently demonstrated
in yeast that global protein degradation is modulated after
exposure to a broad range of DNA damaging agents including
the SN2 alkylating agent methyl methanesulfonate (MMS)
(17). Our results have established a role for both the proteasome and vacuole in recovery after exposure to MMS. These
experiments identified the regulation of protein degradation
as a critical factor for determining cell fate after exposure to
DNA damaging agents. Thus, the molecular mechanism for
the anticancer activity in MM patients treated with melphalan
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Figure 1. Protein degradation assay time-course outline. AA, alkylating agent; PI, proteasome inhibitor; LI, lysosome inhibitor.

and bortezomib may involve perturbation of global protein
metabolism.
Like the proteasome, the lysosome is responsible for
degrading proteins in the cell. However, the lysosome is
responsible for bulk turnover of proteins by the non-selective
process of autophagic uptake (23-26). The lysosome is also
known to be involved in the activation of apoptotic pathways
(27-29), causing cell death by necrosis and the upregulation
of the autophagic pathway can lead to autophagic cell death
(30,31). Therefore, drugs such as chloroquine, which inhibits
lysosome-mediated protein degradation, have become of
interest in cancer research (32-36).
In this study, we investigate the differences in protein
metabolism between a MM cell line (CCL-155) and a noncancerous B lymphocyte cell line (CCL-156). These two cell
lines were derived from the peripheral blood of male patients
by the same researcher during the same time period (37,38).
We observed that both protein synthesis and degradation
occurred at a higher rate in CCL-155 cells. We demonstrated
that alkylating agents can reduce the level of global protein
degradation in both cell lines, but that CCL-156 cells are
affected to a greater extent. Our data establish that growth
inhibition of MM cells from the combined exposure to
melphalan and proteasome inhibitors does not result from a
gross reduction in global protein degradation. Using a drug
cocktail containing both chloroquine and proteasome inhibitor
we present evidence that protein metabolism in MM cells is
aberrant and propose that this metabolic state contributes to
chemoresistance.

Hill, MA) dye exclusion with triplicate measurements. Dead
cells were excluded from the investigation. Viabilities between
80-95% were typical for both cell lines.

Materials and methods

Measurement of global protein synthesis. Our protocol for
measuring global protein synthesis was adapted from the
protocols of Pong et al (39) and Mans and Novelli (40). Cultures
of CCL-155 and CCL-156 cells were incubated under standard
conditions until the cell density reached ~1x106 cells/ml. Both
cell lines were processed simultaneously in the following
manner. Cultures (5 ml) were resuspended in an equal volume
of methionine-free RPMI media supplemented with 10 µCi/ml
L-[35S]-methionine (>1,000 Ci/mmol) (Perkin-Elmer, Boston,
MA) and quickly mixed by pipetting. Aliquots (60 µl) were
immediately removed in duplicate and added to a Whatman
No. 3MM chromatography 2.3 cm filter disk (zero time point)
which was briefly dried with lightly compressed air for 15 sec.
Next, the filter disks were placed in an ice-cold 10% trichloroacetic acid (TCA) (Sigma-Aldrich) bath for 60 min to allow
intact proteins to precipitate onto the filter disk followed
by a 30-min wash in an ice-cold 5% TCA bath. The above
steps were repeated for the 30 and 60-min time points. Two
untreated filter disks were placed in the 10% TCA bath prior
to the experiment and carried through the entire procedure to
determine background counts per minute (CPM). Filter disks
were collected, dried overnight, added to 5-ml scintillation
fluid and subjected to scintillation counting with a Beckman
6500 scintillation counter. Relative CPM incorporated were
calculated by averaging the duplicate CPM readings and
subtracting both the background CPM and the zero time point
CPM from each timepoint.

Cell lines, culture media and materials. Melphalan (MP
Biomedicals, Solon, OH) and MG-132 (EMD Chemicals,
Gibbstown, NJ) were dissolved in DMSO (Sigma-Aldrich,
St. Louis, MO) at a stock concentration of 10 mM.
Chloroquine (MP Biomedicals) was dissolved in H2O to the
same concentration and all solutions were stored at -20˚C.
Methyl methanesulfonate (MMS) was purchased from Acros
Organics (Geel, Belgium). CCL-155 (RPMI-8226) and
CCL-156 (RPMI‑1788) cell lines (ATCC, Manassas, VA) were
maintained and assayed in untreated sterile tissue culture
flasks or plates containing RPMI-1640 media supplemented
with 20% FBS (HyClone, Logan, UT) and 100 U/ml penicillin
and 100 µg/ml streptomycin (MP Biomedicals) in a humidified incubator at 37˚C with 5% CO2 (standard conditions). Both
cell lines were maintained at a density of 0.50-2.0x106 cells/ml
under sterile conditions. Prior to each assay, cell density and
viability was determined using Trypan Blue (Alfa Aesar, Ward

Measurement of global protein degradation. Our protocol
for measuring global protein degradation was adapted
from the protocols of Rock et al (41) and Meriin et al (42)
(Fig. 1). Cultures of either CCL-155 or CCL-156 cells at
~1x106 cells/ml were resuspended in methionine-free RPMI
media supplemented with 10 µCi/ml L-[35S]-methionine
and incubated under standard conditions for 1 h. Next,
cells were washed with phosphate-buffered saline (PBS)
(MP Biomedicals) and resuspended in the same media with
0.2 mg/ml DL-methionine (Calbiochem, Los Angeles, CA).
The culture was then split into separate 5 or 10-ml cultures
and preincubated with appropriate drugs or vehicle for 1 h.
Next, cycloheximide (MP Biomedicals) was added to each
culture at a final concentration of 100 µg/ml, and 450 µl
aliquots were immediately removed in duplicate and added to
TCA (10% final concentration) at appropriate time intervals.
Samples were mixed by brief vortexing, placed on ice for 1 h
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Figure 2. Protein synthesis profile for CCL-155 and CCL-156 cells. Actively
growing cultures were incubated under standard conditions in methionine
depleted RPMI media supplemented with L-[35S]-methionine. Aliquots were
removed in duplicate every 30 min, processed as outlined in Materials and
methods and relative CPM incorporated was calculated. Data are plotted as
the mean ± SE of three independent experiments. ◼, CCl-155; ▲, CCL-156.

and centrifuged in a microfuge at maximum speed for 5 min.
Aliquots of supernatant were removed and subjected to scintillation counting with a Beckman 6500 scintillation counter.
Percent degradation was calculated by averaging the duplicate
CPM readings and using the following equation: % degradation = [(Avg CPM time point X/Avg CPM time point zero) - 1]
x 100%. The increase in CPM detected in the supernatant
corresponds to the release of free amino acids over time.
Cell proliferation test. Media was delivered to a 96-well plate
so that the final volume, with drugs and cells included, would
be 150 µl/well. The drugs at 10-mM stock concentrations were
serially diluted with media so that delivering 15 µl of drugs
to a well would yield the appropriate working concentrations.
Cells were diluted in media so that delivering 90 µl would seed
7,500 cells/well. Media-only wells were included to determine
background. The assay was incubated for 72 h under standard
conditions in triplicate, and viability was determined using the
CellTiter 96® AQueous One Solution Cell Proliferation Assay
(Promega, Madison, WI) according to the manufacturer's
protocol. Absorbance (abs) was read using a Spectramax 250
Plate Reader (Molecular Devices, Sunnyvale, CA) at 490 nm
to determine viability and 600 nm to determine non-specific
abs. The 600 nm abs was subtracted from the 490 nm abs to
obtain the adjusted abs. The adjusted abs for each treatment
was averaged, and the average adjusted abs of media-only
wells was deducted from the average adjusted abs of each
treatment to obtain the final abs.
Statistical analysis. Statistical significance was determined
using unpaired two-tailed Student's t-tests with a 95% confidence interval using the built-in statistical analysis tool in the
GraphPad Prism software program. Linear regression analysis
was performed using Microsoft Office Excel 2007.
Results
Rates of global protein synthesis and degradation for the
CCL-155 and CCL-156 cell lines. In general, we observed that
protein metabolism occurred at a faster rate for the MM cell
line, CCL-155, than the immortalized B-cell line, CCL-156
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Figure 3. Percent protein degradation per hour for CCL-155 and CCL-156
cells. Actively growing cultures were incubated under standard conditions
in methionine depleted RPMI media supplemented with L-[35S]-methionine
for 1 h. Cells were washed and resuspended in the same media with excess
DL-methionine. Next, cells were incubated for 1 h and cycloheximide was
added to each culture. Duplicate aliquots were removed immediately and
60 min later, processed as outlined in Materials and methods and percent
degradation was calculated. Data are plotted as the mean ± SE of three independent experiments.

(Figs. 2 and 3). To measure global protein synthesis, actively
growing cultures were incubated with L-[35S]-methionine.
The level of protein synthesis was determined by measuring
the amount of radioactivity incorporated into intact cellular
proteins (Materials and methods). Fig. 2 indicates that protein
synthesis for both cell lines is linear, and that the level of
radioactivity incorporated into intact proteins reaches 7892
CPM on average for CCL-155 cells after 1-h incubation with
[35S]-methionine, while the CCL-156 cells reach an average
of 4563 CPM under the same conditions. At the 60-min time
point the rate of protein synthesis for CCL-155 is about 1.7-fold
greater than the rate for the CCL-156 cell line (P=0.001). This
is consistent with transcriptional profiling data which showed
that the genes involved in protein synthesis are upregulated in
MM cells compared to normal plasma cells (43).
To measure global protein degradation, actively growing
cultures were incubated (pulse) with L-[35S]-methionine for
1 h followed by incubation (chase) with unlabelled methionine
for 1 h (Fig. 1). Next, cycloheximide was added to stop protein
synthesis, and duplicate aliquots were immediately removed
and processed to determine the background level of radioactivity (time zero). After 1-h incubation in cycloheximide
and unlabelled methionine duplicate aliquots were removed
and processed. This methodology provided consistency with
measurements made in the presence of drugs (see below).
Percent protein degradation was calculated relative to
the level of radioactivity at time zero. For CCL-155 cells, we
observed that about 30% of the cellular proteins had been
degraded by 1 h (Fig. 3). This value is in good agreement
with previous protein degradation measurements in human
cell cultures (41,44). Fig. 3 shows that the average rate of
protein degradation was 5 times greater for CCL-155 cells
(P<0.05), with CCL-156 cells degrading about 6% of the
cellular proteins in 1 h. It should be noted that the CCL-155
cells consistently grow at a slower rate than the immortalized
CCL-156 cells (Fig. 4). Therefore, the differences we observed
in protein metabolism cannot be attributed to a gross difference in intrinsic growth rates for these cell lines in culture.
Effect of an alkylating agent on global protein degradation.
The above protein degradation protocol was followed, but
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Figure 4. Growth curve for CCL-155 and CCL-156 cells. Actively growing
cultures were diluted to 0.20x10 6 cells/ml and incubated under standard
conditions. Viable cell density was determined every 24 h over a 72-h period
from three independent measurements using trypan blue dye exclusion. Data
are plotted as the mean ± SE of three independent experiments. ◼, CCl‑155;
▲, CCL-156.

Figure 5. Protein degradation profile for CCL-155 cells treated with MMS
or untreated. Cells were treated as in Fig. 3 with the following exceptions.
After resuspending in media containing excess DL-methionine the culture
was split and exposed to 0.05% MMS or untreated for 1 h prior to addition
of cycloheximide. After addition of cycloheximide duplicate aliquots were
removed every 15 min for 1 h. Data are plotted as the mean ± SE of at least
three independent experiments. ◼, No MMS; ▲, 0.05% MMS.

included addition of the alkylating agent MMS or mock at
the beginning of the chase period; 1 h prior to the addition of
cycloheximide (Fig. 1). This methodology allowed for radioactive labeling prior to dividing the cells for drug treatment,
as well as one hour for expression of MMS-induced genes
before inhibiting protein synthesis by cycloheximide. Addition
of cycloheximide insures radioactive methionine will not be
recycled. Fig. 5 indicates that global protein degradation is
linear over this time period for treated and untreated CCL-155
cultures and that treatment with 0.05% MMS results in a
significant decrease in the rate of protein degradation (P<0.05
at 1 h). This is a relatively low MMS dose compared to doses
used for transcriptional profiling experiments for human cells
(45). Nonetheless, this dose causes a 2-fold reduction in the
rate of protein degradation compared to the untreated sample.
It is well known that the 3-methyladenine lesions that
develop in DNA after MMS exposure can block replicative
DNA polymerases (46); however, our observation suggest
that the antiproliferative effects of alkylating agents may
include the modulation of global protein degradation. It should

Figure 6. Protein degradation assay for CCL-155 and CCL-156 cells treated
with combinations of melphalan, MG132 and chloroquine. Cells were treated
as in Fig. 3 with the following exceptions. After resuspending in media containing excess DL-methionine the culture was split and exposed to appropriate
drugs for 1 h at the following concentrations: melphalan, 500 µM; MG132,
50 µM; chloroquine, 1 mM. Data are plotted as the mean ± SE of at least three
independent experiments relative to the untreated culture. *P<0.05.

Figure 7. Cell proliferation test for CCL-155 and CCL-156 cells treated with
combinations of melphalan, MG132 and chloroquine. Approximately 7,500
cells were seeded in a 96-well plate in triplicate and incubated under standard
conditions in the presence or absence of drugs for 72 h and cell viability was
determined. Melphalan, 5 µM; MG132, 0.2 µM; chloroquine, 5 µM. Data are
plotted as the mean ± SE of at least three independent experiments. *P<0.05.

be noted that this result is in contrast to data obtained with
yeast cells which showed that treatment with MMS actually
increased the rate of protein degradation (17).
Global protein degradation is aberrant for CCL-155 cells.
Next, we compared the effects of different drugs on the levels of
global protein degradation for the CCL-155 and CCL-156 cell
lines. Side-by-side comparisons of eight different drug treatments were performed as outlined in Fig. 1. For these assays,
we used the clinically relevant alkylating agent melphalan, the
proteasome inhibitor MG132 and the lysosomal inhibitor chloroquine. Proteasome and lysosome inhibitor concentrations
were chosen based on literature values that yielded significant
inhibition of protein degradation in human cells (42,47-50).
We chose a melphalan concentration that provided significant
disparity in the effect on protein degradation between the two
cell lines. Because acute drug treatment is required for this
assay, we used a melphalan concentration much higher than
what is clinically relevant.
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Table I. Percent difference in the average relative levels of protein degradation or cell proliferation between the CCL-155 and
CCL-156 cell lines.
Treatment with melphalan/MG132/chloroquine
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+/-/-/+/-/-/+
+/+/+/-/+
+/+/+
-/+/+
Protein degradation
Cell proliferation

54.0
32.3

19.7
-15.0

46.1
9.3

42.6
19.2

-7.4
60.5

34.4
28.2

46.1
41.3

Bold indicates correlation between protein degradation and cell proliferation (P=0.066).

Collectively, we observed that global protein degradation
in CCL-155 cells is less affected by addition of drugs to the
media. Fig. 6 indicates that addition of 500 µM melphalan to
the media results in a slight but insignificant decrease in the
level of protein degradation for CCL-155 cells, but that the
level of protein degradation for CCL-156 cells is reduced over
50% (P<0.05). In general, treatment of CCL-155 with any drug
combination, other than melphalan alone, resulted in a 30-50%
decrease in the level of protein degradation. Treatment with
50 µM MG132 resulted in a roughly 50% reduction in the
level of protein degradation for both cell lines. Treatment with
1 mM chloroquine or melphalan plus MG132 caused the level
of protein degradation for CCL-156 to be reduced at least twice
as much as CCL-155 (P<0.05). Treatment with melphalan
plus chloroquine had a similar effect on the level of protein
degradation for both cell lines. Treatment with all three drugs
reduced the level of protein degradation in CCL-156 about
twice as much as the levels in CCL-155 (P<0.05). Treatment of
cells with MG132 plus chloroquine reduced protein degradation in both cell lines, but the level of protein degradation for
CCL-156 cells was drastically reduced to about 5% of the level
for untreated CCL-156 cells. This level of protein degradation
is approximately 10-fold less than that observed for similarly
treated CCL-155 cells (P<0.05). For most drug treatments,
we observed a statistically significant difference in the level
of protein degradation between CCL-155 and CCL-156 cells.
This indicates that global protein degradation is grossly aberrant in CCL-155 cells.
CCL-155 cells are less sensitive to the growth inhibition
effects of various drug cocktails. The effects of different
combinations of melphalan, MG132 and chloroquine on cell
proliferation were investigated. Drug concentrations were
chosen which caused no greater than 30% average growth
inhibition for CCL-155 cells when administered alone.
In general, CCL-155 cells were less sensitive to growth
inhibition by these drug combinations than CCL-156 cells
(Fig. 7). For instance, treatment with melphalan alone,
melphalan plus MG132 or melphalan plus chloroquine resulted
in at least a 2-fold difference between cell lines for average
cell proliferation with these drug combinations exerting more
growth inhibition in CCL-156 cells. No discernable differences
were observed with either MG132 or chloroquine alone, and
growth inhibition with these treatments was minimal in both
cell lines. However, combination of MG132 plus chloroquine
proved to be growth inhibitory only for CCL-156 (P<0.05).

Finally, treatment with all three drugs greatly inhibited cell
proliferation in both cell lines with CCL156 cells exhibiting a
3-fold lower average cell proliferation than CCL-155 cells. It
should be noted that the highest degree of growth inhibition
for CCL-155 cells was achieved only with combined exposure
to melphalan plus MG132, consistent with clinical use of this
drug combination to treat MM (6).
Statistical support for a correlation between proteasomemediated protein degradation and cell proliferation. For
several drug treatments, we noticed that differences in the
relative protein degradation between the cell lines often
corresponded to similar differences in relative cell proliferation (comparing Figs. 6 and 7). Therefore, we sought to
determine if there was a correlation between the level of relative global protein degradation and the relative level of cell
proliferation for CCL-155 and CCL-156 cells. Our analysis
included data points derived from treatments which included
melphalan alone and MG132 in any combination. For this
analysis, we took the average values for the relative level of
protein degradation or cell proliferation and calculated the
difference between CCL-155 and CCL-156 (CCL-155 minus
CCL-156) for each treatment (Table I). We next plotted the
differences for protein degradation versus the differences for
cell proliferation. Using linear regression analysis with these
five data points we obtained an r2 value of 0.7278 (r=0.8531).
Next, we performed a Student's t-test assuming three degrees
of freedom and obtained a P-value of 0.066. This correlation
was abolished when we considered treatment with chloroquine
in the absence of MG132.
Discussion
Protein synthesis and degradation are thought to be ongoing
processes in mammalian systems, and proteins are hypothesized to exist in a dynamic equilibrium within the cell (51).
Our results show that the intrinsic rate of protein metabolism
for the MM cell line CCL-155 is elevated compared to the
non-cancerous B lymphocyte cell line CCL-156. Significantly
higher rates were observed for both global protein synthesis
and global protein degradation in CCL-155 cells (Figs. 2
and 3). It is well known that protein metabolism is elevated
in a typical cancer cell (52-54); however, relatively speaking,
MM is a slow growing cancer and this is reflected in cultured
cells (Fig. 4). Therefore, considering cell doubling time, it can
be extrapolated that global protein synthesis and degradation
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in CCL-155 is elevated roughly 4-fold and 12-fold per cell
generation, respectively. The deficit in the rate of synthesis vs.
degradation may in part explain the development of uremia in
some MM patients (55).
Our measurements of global protein degradation revealed
that CCL-155 did not have a significant change in the level
of protein degradation after exposure to melphalan, whereas
MMS caused a 2-fold reduction in protein degradation. The
discrepancy between our results with melphalan and MMS
can be explained by the fact that the melphalan concentration
in our assays is roughly 10-fold less than the MMS concentration. Furthermore, Lawley and Thatcher have determined that
in vivo MMS preferentially alkylates proteins (56) whereas
melphalan has equivalent reactivity with nucleic acids and
proteins (57).
In contrast, exposure of CCL-156 cells to the same
concentration of melphalan resulted in a greater than 2-fold
reduction of global protein degradation compared to untreated
CCL-156 cells (Fig. 6). Additionally, melphalan was observed
to be more toxic to CCL-156 cells (Fig. 7). Indicators of differences in protein metabolism and stress response phenotypes
between MM cells and B cells can be found in the literature.
For instance, transcriptional profiling experiments have shown
that genes involved in the unfolded protein response, protein
synthesis and the stress response are upregulated in patientderived MM cells compared to plasma cells derived from
an unaffected twin (43). Additional experiments showed that
XBP1, which mediates the unfolded protein response, as well
as a group of disulfide isomerase genes, is expressed at a higher
level in CCL-155 than in mature B cells (58). Considering that
global protein synthesis and degradation is increased in MM
cells (Figs. 2 and 3), the data suggests that MM cells are better
prepared to process and replace alkylation damaged proteins.
We primarily observed that cell line CCL-155 showed
significantly higher levels of global protein degradation for
varying combinations of melphalan, MG132 and chloroquine than cell line CCL-156. The most notable difference
between CCL-155 and CCL-156 was observed when both the
proteasome and lysosome were inhibited. The greatest growth
inhibition for both cell lines was observed when melphalan
plus MG132 were included in the drug cocktail even though
the protein degradation level for CCL-155 remained at about
60% of the untreated level. The growth inhibition result with
CCL-155 is consistent with a previous published study (4);
however, it is surprising to observe that the non-cancerous cell
line actually appears more sensitive to this drug combination.
This observation may help explain the hematological toxicities and compromised immune responses observed in clinical
trials (6). Importantly, our results establish that the sensitivity
of CCL-155 to melphalan plus MG132 cannot be attributed to
a gross reduction in protein degradation. Overall, we surmise
that the increased rate of protein metabolism in CCL-155
cells renders this cell line less prone to modulation of protein
degradation by proteasome inhibitors, lysosomal inhibitors
and alkylating agents.
Several studies have identified both the proteasome and
lysosome (or counterpart) to be important for recovery from
DNA damaging agents (14-19). Our previous results in yeast
showed that inhibition of proteasomal and vacuolar proteases
inhibited growth in cultures treated with MMS (17). Here,

we observe similar results with proteasome and lysosome
inhibitors. One interesting result is observed when we treat
cells with melphalan plus chloroquine. For this drug cocktail,
protein degradation was reduced to about 60% of the untreated
level for both cell lines, but this treatment proved much more
effective at inhibiting growth for CCL-156. Chloroquineinduced destabilization of the lysosomal membrane has
been shown to cause release of pro-death signals into the
cytosol (29,34,35). Differential destabilization of the lysosomal membrane between these cell lines may explain this
observation. On the other hand, this result may indicate that a
lysosomal function other than protein degradation is required
for recovery from alkylation damage in CCL-156 cells such
as the metabolism of damaged carbohydrates and/or lipids.
Another interesting observation is that treatment of CCL-155
with melphalan plus chloroquine results in the same degree
of growth inhibition as melphalan alone while treatment with
melphalan plus MG132 is the most growth inhibitory treatment for CCL-155. Furthermore, exposure of either cell line
to melphalan plus MG132 plus chloroquine does not increase
growth inhibition compared to treatment with melphalan
plus MG132 for either cell line. These data are consistent
with studies in yeast where the proteasome proved to be the
protein degradation machinery most important for recovery
from alkylating agents (17).
Upon further analysis of our protein degradation and cell
proliferation data, we find fairly good evidence for a correlation between the degree of protein degradation reduction and
the degree of growth inhibition for treatments which include
melphalan alone and MG132 in any combination (comparing
Figs. 6 and 7, summarized in Table I). Statistical analysis of
the data resulted in a P-value of 0.066, which suggests that
drug treatments that result in a greater reduction in protein
degradation levels for CCL-156 compared to CCL-155 also
result in greater growth inhibition for CCL-156 compared to
CCL-155. This correlation was not observed when we also
considered treatment with chloroquine in the absence of
MG132, further indicating that the proteasome has a more
prominent role in recovery from alkylating agents. Assuming
the data obtained with the non-cancerous CCL-156 cell line
to represent a normal response, these data infer that CCL-155
cells are resistant to pharmaceutical modulation of global
protein degradation rates and that this phenotype contributes
to the chemoresistance of MM cells. Our data provides new
insight into the metabolic state of MM cells and is important
to consider as new therapies are developed to treat MM.
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